Remegen Co
Remegen Co., also known as Remegen, is a leading biopharmaceutical company headquartered in China (CN). Founded in 2015, the company has rapidly established itself in the oncology and autoimmune disease sectors, focusing on innovative therapies that address unmet medical needs. With a strong presence in both domestic and international markets, Remegen is renowned for its advanced monoclonal antibody products, particularly in the field of cancer treatment. Their flagship therapies are distinguished by their unique mechanisms of action and commitment to improving patient outcomes. Recognised for its significant contributions to the biopharmaceutical landscape, Remegen has achieved notable milestones, including successful clinical trials and strategic partnerships that enhance its market position. As a forward-thinking organisation, Remegen continues to drive advancements in biomedicine, solidifying its reputation as a key player in the industry.
DitchCarbon Score
How does Remegen Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Remegen Co's score of 2 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Remegen Co's reported carbon emissions
In 2022, Remegen Co reported total carbon emissions of approximately 39,551,550 kg CO2e, all of which were classified under Scope 2 emissions, indicating that these emissions were primarily associated with the electricity and energy used in their operations. In 2021, the company recorded emissions of about 22,183,040 kg CO2e, also entirely from Scope 2. The 2020 emissions were approximately 16,414,190 kg CO2e, with 4,136,080 kg CO2e from Scope 1 and 12,278,120 kg CO2e from Scope 2. Despite the significant increase in emissions from 2021 to 2022, there are currently no publicly disclosed reduction targets or climate pledges from Remegen Co. The absence of specific reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As the industry increasingly prioritises sustainability, Remegen Co's future commitments will be crucial in aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 4,136,080 | - | - |
| Scope 2 | 12,278,120 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Remegen Co is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
